9:06 am ET October 10, 2023
Beam Therapeutics’ BEAM proprietary base-editing technology potentially enables the development of a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA, thereby minimizing errors.
The company is pursuing two primary approaches depending on tissue type in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy using engineered human cells.
BEAM is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for sickle cell disease (SCD). It has successfully consented enough patients projected to both fill the sentinel cohort and initiate the expansion cohort of the early-stage study.
Apart from BEAM-101, the company is evaluating BEAM-201, a therapy designed to create allogeneic CD7, targeting CAR-T cells resistant to fratricide and immunosuppression. BEAM-201 is actively enrolling patients at multiple clinical sites, in a phase I/II study for treating patients with T-cell leukemia and T-cell lymphoblastic lymphoma, a severe disease affecting children and adults, and potentially other CD7+ malignancies.
The company also has two pre-clinical candidates —BEAM-301 and BEAM-302 — in its portfolio for genetic diseases.
BEAM has initiated IND-enabling studies for both candidates and plans to submit a regulatory application to begin clinical studies in the first half of 2024.
While the company is yet to have an approved marketable product in its pipeline, its collaboration deals help access capabilities and resources to support the ongoing therapeutic programs.
BEAM collaborated with Pfizer PFE in 2021, focusing on using its gene-editing technology to create treatments for rare genetic diseases that affect the liver, muscles and the central nervous system. It is conducting the research work for three specific gene-editing programs. If these programs prove effective in clinical studies, Pfizer can choose to help develop and sell them globally, with both companies sharing the costs and profits.
Recent BEAM News
- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) • GlobeNewswire Inc. • 06/26/2024 10:30:00 AM
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease • GlobeNewswire Inc. • 06/14/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:42:12 PM
- Beam Therapeutics to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 10:30:00 AM
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress • GlobeNewswire Inc. • 05/14/2024 08:00:00 PM
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference • GlobeNewswire Inc. • 05/08/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:19:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:09:10 AM
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 10:30:00 AM
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) • GlobeNewswire Inc. • 03/26/2024 10:30:00 AM
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences • GlobeNewswire Inc. • 02/28/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:40:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:43:02 AM
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones • GlobeNewswire Inc. • 02/27/2024 11:30:00 AM
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/31/2024 09:47:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:18 AM
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM